Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Dermatology
•
Hidradenitis Suppurativa
•
Primary Care
How would you manage a patient with hidradenitis suppurativa and inflammatory arthritis (RA vs. PsA)?
Pt has not responded to Humira or Cosentyx. Pt is declining to have any infusion options.
Related Questions
How do you approach treatment intensification in patients with RA and low disease activity but not in remission, considering the potential risks of increased immunosuppression?
How would you approach management of a patient with longstanding history of SLE, but having active psoriasis?
How do you approach medication management in patients with RA when transitioning from csDMARD triple therapy to anti-TNF?
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?
How do you optimize retinopathy screening schedules for patients on hydroxychloroquine while also prioritizing cost-effectiveness?
Would you continue TNF-inhibitor in a patient with psoriatic arthritis who has had multiple nonmelanoma skin cancers requiring Mohs surgery?
How do you approach management of DMARDs and biologics in a patient with active RA, but frequent recurrent simple UTIs?
How would you approach management of a patient who develops squamous cell skin cancer while on abatacept?
Can Xolair (omalizumab) be safely used in combination with biologics for patients with rheumatic disease?